A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density.
Whether biochemical markers can predict improvement in reduced bone mineral density (BMD) associated with thyrotoxicosis in unclear. We investigated the relationship between serum osteocalcin (OC), bone-specific alkaline phosphatase (b-ALP), serum deoxypyridinoline (Sdpd) and pyridinoline (Spyr), 24-hour urinary deoxypyridinoline (Udpd), and BMD in 17 thyrotoxic patients during 1 yr of treatment. Coinciding with euthyroidism at 4-8 weeks, there was a peak in b-ALP and OC and a prompt fall into the normal range in Udpd and Sdpd, but not Spyr, levels. Mean b-ALP continued to be raised at week 52 when it was inversely correlated with BMD. Mean BMD rose approximately 6%, P < 0.01, over 1 yr. Coupling indices were calculated as a measure of bone balance and, at diagnosis, was [minus4.26 in favor of bone resorption and rose with treatment in favor of bone formation: weeks 2: -0.23; 4: +4.01; 8: +4.37; 12: +4.44; 24: +2.32; and 52: +1.56. Bone turnover is balanced within 2 weeks of starting treatment for thyrotoxicosis. Udpd accurately indicates thyrotoxic bone resorption. Serum b-ALP indicates continuing bone formation and, at 1 yr, may provide a marker for low BMD. OC, Sdpd, and Spyr are less sensitive in documenting bone remodeling during treatment of thyrotoxicosis.
Siddiqi
A
A
Department of Endocrinology, St. Bartholomew's and the Royal London Hospital, England. ASiddiqi@mds.qmw.ac.uk
Burrin
J M
JM
Noonan
K
K
James
I
I
Wood
D F
DF
Price
C P
CP
Monson
J P
JP
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism*; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D005544:Forecasting; D006111:Graves Disease / Q000378:metabolism*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D013971:Thyrotoxicosis / Q000188:drug therapy / Q000378:metabolism
D013956:Antithyroid Agents; D015415:Biomarkers; D002231:Carbimazole